Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Recommendations

Info

240 Applying Pharmacogenomics in Therapeutics103. Leung TF, Sy HY, Ng MC, et al. Asthma and atopy are associated with chromosome17q21 markers in Chinese children. Allergy 2009;64:621–8.104. Tse SM, Tantisira K, Weiss ST. The pharmacogenetics and pharmacogenomics ofasthma therapy. The Pharmacogenomics Journal 2011;11:383–92.105. Israel E. Genetics and the variability of treatment response in asthma. The Journal ofAllergy and Clinical Immunology 2005;115:S532–8.106. Duan QL, Tantisira KG. Pharmacogenetics of asthma therapy. Current PharmaceuticalDesign 2009;15:3742–53.107. Finkelstein Y, Bournissen FG, Hutson JR, Shannon M. Polymorphism of the ADRB2gene and response to inhaled beta-agonists in children with asthma: A meta-analysis.The Journal of Asthma 2009;46:900–5.108. Carroll CL, Stoltz P, Schramm CM, Zucker AR. Beta2-adrenergic receptor polymorphismsaffect response to treatment in children with severe asthma exacerbations.Chest 2009;135:1186–92.109. Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected bybeta2-adrenergic receptor genotype in subjects with persistent asthma. The Journal ofAllergy and Clinical Immunology 2006;118:809–16.110. Bleecker ER, Nelson HS, Kraft M, et al. Beta2-receptor polymorphisms in patientsreceiving salmeterol with or without fluticasone propionate. American Journal ofRespiratory and Critical Care Medicine 2010;181:676–87.111. Cabana MD, Lara M, Shannon J. Racial and ethnic disparities in the quality of asthmacare. Chest 2007;132:810S–7S.112. Moore PE, Ryckman KK, Williams SM, Patel N, Summar ML, Sheller JR. Geneticvariants of GSNOR and ADRB2 influence response to albuterol in African-Americanchildren with severe asthma. Pediatric Pulmonology 2009;44:649–54.113. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonaryarterial hypertension. Journal of the American College of Cardiology 2009;54:S55–66.114. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatmentof pulmonary hypertension: The Task Force for the Diagnosis and Treatmentof Pulmonary Hypertension of the European Society of Cardiology (ESC) and theEuropean Respiratory Society (ERS), endorsed by the International Society of Heartand Lung Transplantation (ISHLT). European Heart Journal 2009;30:2493–537.115. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiologicalstudy of pulmonary arterial hypertension. The European Respiratory Journal 2007;30:104–9.116. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: Baselinecharacteristics from the REVEAL Registry. Chest 2010;137:376–87.117. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonaryarterial hypertension in the current antiretroviral therapy era. American Journalof Respiratory and Critical Care Medicine 2008;177:108–13.118. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertensiondiagnosed by right heart catheterisation in sickle cell disease. The EuropeanRespiratory Journal 2012;39:112–18.119. Machado RF, Gladwin MT. Pulmonary hypertension in hemolytic disorders: Pulmonaryvascular disease: The global perspective. Chest 2010;137:30S–8S.120. Austin ED, Loyd JE. Heritable forms of pulmonary arterial hypertension. Seminars inRespiratory and Critical Care Medicine 2013;34:568–80.121. Zhang X, Zhang W, Ma SF, et al. Hypoxic response contributes to altered gene expressionand precapillary pulmonary hypertension in patients with sickle cell disease.Circulation 2014;129:1650–58.
Applying Pharmacogenomics in the Therapeutics of Pulmonary Diseases241122. Yao W, Mu W, Zeifman A, et al. Fenfluramine-induced gene dysregulation in humanpulmonary artery smooth muscle and endothelial cells. Pulmonary Circulation 2011;1:405–18.123. Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associatedwith fenfluramine exposure: Report of 109 cases. The European Respiratory Journal2008;31:343–8.124. Barst RJ, Abenhaim L. Fatal pulmonary arterial hypertension associated with phenylpropanolamineexposure. Heart 2004;90:e42.125. Seferian A, Chaumais MC, Savale L, et al. Drugs induced pulmonary arterial hypertension.Presse Medicale 2013;42:e303–10.126. Yakel DL, Jr., Eisenberg MJ. Pulmonary artery hypertension in chronic intravenouscocaine users. American Heart Journal 1995;130:398–9.127. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primarypulmonary hypertension. International Primary Pulmonary Hypertension StudyGroup. The New England Journal of Medicine 1996;335:609–16.128. Naeije R, Vanderpool R. Pulmonary hypertension and chronic mountain sickness. HighAltitude Medicine & Biology 2013;14:117–25.129. Xu XQ, Jing ZC. High-altitude pulmonary hypertension. European Respiratory Review2009;18:13–17.130. Seferian A, Simonneau G. Therapies for pulmonary arterial hypertension: Where arewe today, where do we go tomorrow? European Respiratory Review 2013;22:217–26.131. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteriestransforms prostaglandin endoperoxides to an unstable substance that inhibits plateletaggregation. Nature 1976;263:663–5.132. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension.The New England Journal of Medicine 2002;346:896–903.133. Lee YH, Song GG. Meta-analysis of randomized controlled trials of bosentan for treatmentof pulmonary arterial hypertension. The Korean Journal of Internal Medicine2013;28:701–7.134. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonaryarterial hypertension. The New England Journal of Medicine 2013;369:809–18.135. Clarke M, Walter C, Agarwal R, Kanwar M, Benza RL. Macitentan (Opsumit) for thetreatment of pulmonary arterial hypertension. Expert Review of Clinical Pharmacology2014;7:415–21.136. Hong IS, Coe HV, Catanzaro LM. Macitentan for the treatment of pulmonary arterialhypertension. The Annals of Pharmacotherapy 2014;48:538–47.137. Montani D, Chaumais MC, Savale L, et al. Phosphodiesterase type 5 inhibitors inpulmonary arterial hypertension. Advances in Therapy 2009;26:813–25.138. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitorsfor the treatment of pulmonary hypertension. The European Respiratory Journal2008;32:198–209.139. Lang M, Kojonazarov B, Tian X, et al. The soluble guanylate cyclase stimulatorriociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.PLoS One 2012;7:e43433.140. Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterialhypertension. Journal of the American College of Cardiology 2013;62:D13–21.141. Harrison RE, Flanagan JA, Sankelo M, et al. Molecular and functional analysis identifiesALK-1 as the predominant cause of pulmonary hypertension related to hereditaryhaemorrhagic telangiectasia. Journal of Medical Genetics 2003;40:865–71.142. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonaryarterial hypertension. Journal of the American College of Cardiology 2009;54:S32–42.
Page 1:
ApplyingPharmacogenomicsin Therapeu
Page 5 and 6:
ApplyingPharmacogenomicsin Therapeu
Page 7:
DedicationWe dedicate this book to
Page 10 and 11:
viiiContentsChapter 10 Pharmacogeno
Page 13 and 14:
EditorsXiaodong Feng, PhD, PharmD,
Page 15 and 16:
ContributorsWeiguo Chen, PhDDepartm
Page 17 and 18:
1Concepts inPharmacogenomics andPer
Page 19 and 20:
Concepts in Pharmacogenomics and Pe
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
2Principles ofPharmacogeneticBiotec
Page 51 and 52:
Principles of Pharmacogenetic Biote
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65:
Page 68 and 69:
52 Applying Pharmacogenomics in The
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 91 and 92:
4 ApplyingPharmacogenomicsin Drug D
Page 93 and 94:
Applying Pharmacogenomics in Drug D
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
5 Pharmacogenomicsand Laboratory Me
Page 113 and 114:
Pharmacogenomics and Laboratory Med
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157:
Page 160 and 161:
144 Applying Pharmacogenomics in Th
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207: 190 Applying Pharmacogenomics in Th
Page 217 and 218: 8Clinical Applicationsof Pharmacoge
Page 219 and 220: Pharmacogenomics of CNS Disorder Tr
Page 237 and 238: 9 ApplyingPharmacogenomicsin the Th
Page 239 and 240: Applying Pharmacogenomics in the Th
Page 255: Applying Pharmacogenomics in the Th
Page 259 and 260: 10Pharmacogenomics andAlternative M
Page 261 and 262: Pharmacogenomics and Alternative Me
Page 287 and 288: 11 PharmacoeconogenomicsA Good Marr
Page 289 and 290: Pharmacoeconomics of Pharmacogenomi
Page 303 and 304: 5’3’5’3’ 5’3’ 5’3’3
Page 305 and 306: 1 2 3 4 5Vysis LSI BCR/ABL + 9q34 t
Page 307:
BIOMEDICAL SCIENCEApplying Pharmaco
show all

Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?